Temsirolimus - Pfizer

Drug Profile

Temsirolimus - Pfizer

Alternative Names: CCI-779; Cell cycle inhibitor-779; NSC-683864; Torisel

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Johann Wolfgang Goethe Universitatsklinikum; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Consortium; National Comprehensive Cancer Network; NCIC Clinical Trials Group; Pfizer; Wyeth
  • Class Antineoplastics; Macrolides
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma; Mantle-cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Renal cell carcinoma
  • Phase II Acute myeloid leukaemia; Bladder cancer; Glioblastoma; Glioma; Hodgkin's disease; Non-Hodgkin's lymphoma; Thyroid cancer
  • Phase I/II Follicular lymphoma; Head and neck cancer
  • No development reported Colorectal cancer; Lymphoma; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Solid tumours
  • Discontinued Breast cancer; Pancreatic cancer; Soft tissue sarcoma

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, In adolescents, Recurrent, Second-line therapy or greater) in Canada (IV, Injection)
  • 28 Jun 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, In adolescents) in Canada (IV, Injection)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top